Literature DB >> 25724784

Analysis of the bypass angioplasty revascularization investigation trial using a multistate model of clinical outcomes.

Xiao Zhang1, Quanlin Li1, Andre Rogatko1, Mourad Tighiouart1, Regina M Hardison2, Maria Mori Brooks2, Sheryl F Kelsey2, Sanjay Kaul3, C Noel Bairey Merz4.   

Abstract

Current cardiovascular randomized trials typically use composite outcomes. We hypothesized that the Bypass Angioplasty Revascularization Investigation (BARI) outcomes and conclusions would differ using a multistate model relative to the intervention for the composite outcome of death (D) and nonfatal Q-wave myocardial infarction (MI). We used a multistate model which uses transition paths to simultaneously assess multiple end points. Using the 10-year follow-up BARI data, we post hoc analyzed outcomes according to 3 transition paths: (1) from intervention to MI; (2) from intervention to death; and (3) from MI to death. Of 1,829 patients randomized to the intervention of percutaneous transluminal coronary angioplasty or coronary artery bypass grafting (CABG), 700 (38%) experienced the composite event D/MI which included 230 (13%) nonfatal MI and 470 (26%) death without antecedent nonfatal MI, whereas 79 of 230 (34%) experienced death after nonfatal MI. Outcomes of the 3 individual transition paths were analyzed by a multistate model. In contrast to standard survival analyses, after adjustment for baseline clinical covariates, outcomes after percutaneous transluminal coronary angioplasty or CABG were not significantly different for intervention to MI (p = 0.33) or intervention to death (p = 0.23), but MI to death favored CABG (p = 0.02). Deconstruction of the BARI data using a multistate model identifies a significant difference in individual transition-stage outcomes and therefore trial conclusions in contrast to the standard methods of survival analysis. These observations suggest multistate models should be considered in the design and analysis of randomized cardiovascular trials which use composite outcomes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25724784      PMCID: PMC4380580          DOI: 10.1016/j.amjcard.2015.01.543

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

1.  Multi-state models for bleeding episodes and mortality in liver cirrhosis.

Authors:  P K Andersen; S Esbjerg; T I Sorensen
Journal:  Stat Med       Date:  2000-02-29       Impact factor: 2.373

2.  Measures of treatment effectiveness on tumour response and survival: a multi-state model approach.

Authors:  S Chevret; M Leporrier; C Chastang
Journal:  Stat Med       Date:  2000-03-30       Impact factor: 2.373

3.  Multi-state models and outcome prediction in bone marrow transplantation.

Authors:  N Keiding; J P Klein; M M Horowitz
Journal:  Stat Med       Date:  2001-06-30       Impact factor: 2.373

Review 4.  Multi-state models for event history analysis.

Authors:  Per Kragh Andersen; Niels Keiding
Journal:  Stat Methods Med Res       Date:  2002-04       Impact factor: 3.021

5.  Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II).

Authors:  Alfredo E Rodriguez; Julio Baldi; Carlos Fernández Pereira; Jose Navia; Máximo Rodriguez Alemparte; Alejandro Delacasa; Federico Vigo; Daniel Vogel; William O'Neill; Igor F Palacios
Journal:  J Am Coll Cardiol       Date:  2005-08-16       Impact factor: 24.094

6.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease.

Authors: 
Journal:  N Engl J Med       Date:  1996-07-25       Impact factor: 91.245

7.  Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators.

Authors:  A Rodriguez; V Bernardi; J Navia; J Baldi; L Grinfeld; J Martinez; D Vogel; R Grinfeld; A Delacasa; M Garrido; R Oliveri; E Mele; I Palacios; W O'Neill
Journal:  J Am Coll Cardiol       Date:  2001-01       Impact factor: 24.094

8.  The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization Investigation Investigators.

Authors:  K M Detre; M S Lombardero; M M Brooks; R M Hardison; R Holubkov; G Sopko; R L Frye; B R Chaitman
Journal:  N Engl J Med       Date:  2000-04-06       Impact factor: 91.245

9.  A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST)

Authors:  S B King; N J Lembo; W S Weintraub; A S Kosinski; H X Barnhart; M H Kutner; N P Alazraki; R A Guyton; X Q Zhao
Journal:  N Engl J Med       Date:  1994-10-20       Impact factor: 91.245

10.  Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease.

Authors:  W S Weintraub; B Stein; A Kosinski; J S Douglas; Z M Ghazzal; E L Jones; D C Morris; R A Guyton; J M Craver; S B King
Journal:  J Am Coll Cardiol       Date:  1998-01       Impact factor: 24.094

View more
  2 in total

1.  Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn's Disease.

Authors:  Parakkal Deepak; Joel G Fletcher; Jeff L Fidler; John M Barlow; Shannon P Sheedy; Amy B Kolbe; William S Harmsen; Terry Therneau; Stephanie L Hansel; Brenda D Becker; Edward V Loftus; David H Bruining
Journal:  Inflamm Bowel Dis       Date:  2018-07-12       Impact factor: 5.325

2.  Plasma levels of growth differentiation factor-15 are associated with myocardial injury in patients undergoing off-pump coronary artery bypass grafting.

Authors:  Zhize Yuan; Haiqing Li; Quan Qi; Wenhui Gong; Cheng Qian; Rong Dong; Yi Zang; Jia Li; Mi Zhou; Junfeng Cai; Zhe Wang; Anqing Chen; Xiaofeng Ye; Qiang Zhao
Journal:  Sci Rep       Date:  2016-06-17       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.